Algernon Pharmaceuticals (AGNPF) has received a notice of allowance from the United States Patent and Trademark Office for patent application 17/255,364 for its lead chronic kidney disease program drug NP-251. The invention claims the use of Repirinast, either alone or in combination with telmisartan, for the treatment or prophylaxis of renal fibrosis or kidney disease. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection. The Company has been issued corresponding patents in Japan and China, with applications pending in Europe and Canada. Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction mouse model.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.